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Abstract
AIM: To characterize the histopathologic specifications 
of non-alcoholic steatohepatitis (NASH) according to 
age and gender. 
METHODS: An analytical cross-sectional study was 
conducted in two private gastroenterology clinics on 
biopsy proven patients suffering from NASH. Biopsy 
histopathologic findings as well as demographic and 
laboratory data of the patients at the time of biopsy 
were gathered retrospectively from clinical records. 
The grading and staging of histopathologic findings 
were performed according to the Brunt method after 
reevaluation of the slides by a pathologist. Patients 
were divided into two groups according to age (below 
and above 55 years). Mean quantitative grade of all 
pathologic findings were also calculated according to 
Brunt scoring values.
RESULTS: A total number of 77 NASH patients, consist-
ing of 58 males (75.3%) and 19 (24.7%) females with a 
mean age of 41.99 ± 11.80 years (range, 18-70 years), 
were enrolled. The mean age (48.72 ± 13.99 years vs  
39.74 ± 10.16 years, P  = 0.004) and aspartate ami-
notransferase level (75.11 ± 29.68 U/L vs  52.78 ± 
25.00 U/L, P  = 0.002) was significantly higher in female 
patients. Mean quantitative grade of hepatosteatosis 
was significantly higher in females (2.00 ± 0.82 vs  1.59 
± 0.68, P  = 0.031) compared to males. Fifty four per-
cent (34/65) of young patients had mild hepatosteatosis 
(Grade Ⅰ) while only one patient (11.2%) in the older 
group had grade Ⅰ hepatosteatosis. Patients aged ≥ 55 
had significantly more severe hepatosteatosis (Grade Ⅲ) 
(44.4% vs  9.5%, P  = 0.007) and the mean quantitative 
grade of hepatosteatosis was significantly higher among 
them (2.33 ± 0.71 vs  1.56 ± 0.67, P  = 0.002). Multivar-
iate analysis after omitting the confounding role of age 
revealed a higher grade of hepatosteatosis in female 
patients (P  = 0.010).
CONCLUSION: These findings point toward the pos-
sible influence of age in the severity of steatohepatitis, 
portal and lobar inflammation in patients suffering from 
NASH while gender independently might contribute to 
the level of steatohepatitis.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Nonalcoholic steatohepatitis (NASH) is a common cli­
nicopathological entity with a worldwide distribution[1] 
which is defined as a cryptogenic form of  liver disease 
that is often observed in obese patients in the absence of  
identifiable causes such as alcohol abuse, drug toxicity or 
viral infection[2]. Although the disease is often indolent, 
15%-20% of  patients may progress to fibrosis and 7%-17% 
may insidiously develop cirrhosis which is a strong warn­
ing finding in patients’ liver biopsies. Additionally, NASH 
is responsible for the majority of  cryptogenic cirrhosis in 
patients who are at risk of  complications, such as portal 
hypertension and hepatocellular carcinoma[3-7]. According 
to survival rates, population-based studies in the United 
States revealed lower overall survival for patients with 
nonalcoholic fatty liver disease compared to the general 
population[8]. 
Although the etiology of  NASH is unknown, a num­
ber of  co­morbid conditions have been suggested as pre­
disposing factors for the development of  NASH such as 
obesity, type 2 diabetes mellitus, and hyperlipidemia[6,7,9-13]. 
It is assumed that the emergence of  NASH closely resem­
bles the epidemiology of  obesity and diabetes mellitus[14]. 
Recently, there was a parallel increase in the prevalence 
of  obesity, metabolic syndrome (hyperglycemia, visceral 
obesity, hyperlipidemia and hypertension) and NASH. 
As a result, NASH is considered part of  metabolic syn­
drome[15]. Pathogenesis of  metabolic syndrome is based 
on insulin resistance. Aging and reduced physical activity, 
which cause hyperinsulinemia and insulin resistance, result 
in obesity and initiate metabolic syndrome which in turn 
further increases insulin resistance[16]. Considerable differ­
ence in the prevalence of  metabolic syndrome between 
genders has been attributed to sex hormones. Many stud­
ies have shown that women tend to gain weight following 
the menopause and distribution of  their body fat changes 
toward visceral adiposity[17]. There is a considerable in­
crease in the prevalence of  metabolic syndrome in women 
after menopause.
Despite the high prevalence of  NASH, its natural his­
tory is not well understood. To the best of  our knowledge, 
only about 30 cases of  NASH have been described with 
sequential liver biopsies[3,6,7]. Because different sections 
of  metabolic syndrome show significant differences that 
are related to age and gender, there is speculation that the 
clinicopathological features of  NASH may also vary in re­
lation to these factors. The following study was performed 
to evaluate the relationship between age and gender with 
pathologic findings on liver biopsies of  NASH patients.
MATERIALS AND METHODS
Subjects
This analytic cross­sectional study was conducted in two 
private gastroenterology clinics in Tehran, Iran during 
2005-2009. Data were retrospectively collected using the 
medical records of  all eligible subjects who were biopsy 
proven NASH patients that met the following inclusion 
criteria: (1) Histopathologic confirmation of  nonalcoholic 
steatohepatitis; (2) Non­alcohol consumers or intake of  
less than 100 g ethanol per week which was confirmed by 
the attending physician and family members who were 
in close contact with the patient; (3) Negative serologic 
markers of  viral or autoimmune hepatitis, including hepa­
titis B surface antigen, hepatitis C virus antibody (ELISA), 
human immunodeficiency virus antibody (ELISA), 
antinuclear antibodies, anti-smooth muscle antibodies, 
anti­liver/kidney microsomes type 1 antibodies and nega­
tive α­1 antitrypsin; and (4) Not having any other liver 
disorders including metabolic liver diseases (e.g. Wilson’s 
disease and hemochromatosis), drug induced liver disease, 
primary biliary cirrhosis, primary sclerosing cholangitis, 
and biliary obstruction. Moreover, patients with any his­
tory of  jejunoileal bypass surgery, having received hor­
mone replacement therapy for menopause, any usage of  
other drugs known to result in steatosis (e.g. glucocorti­
coids, synthetic estrogens, aspirin, tamoxifen, amiodarone, 
calcium-channel blockers, and methotrexate), pregnancy 
or incomplete medical records were all excluded. Finally, 
77 NASH patients were eligible to enroll in this study. 
Laboratory and histopathologic assessments
Levels of  aminotransferases, including alanine amino­
transferase (ALT) and aspartate aminotransferase (AST), 
alkaline phosphatase (Alk-P), total serum cholesterol 
and triglycerides, low density lipoprotein, high density 
lipoprotein, fasting blood sugar, partial thromboplastin 
time, serum platelet count and serum level of  γ­glutamyl 
transpeptidase were measured using standard techniques. 
In addition, other baseline characteristics such as patients’ 
age and gender and body mass index were recorded for all 
patients. 
According to the guidelines concerning the indica­
tions for liver biopsy, all patients who show no improve­
ment of  liver function after several months of  diet and 
exercise treatment are recommended to undergo a liver 
biopsy. Due to the retrospective nature of  the study, all 
biopsy specimens were recovered from the laboratory 
and reevaluated for histopathologic findings. In order to 
definitely diagnose NASH, all liver biopsy specimens were 
examined for fibrosis, steatosis, hepatocyte ballooning, 
lobar and portal inflammation. The grading and staging 
of  all biopsy specimens were determined based on the 
method proposed by Brunt et al[18]. The categorization of  
the histopathologic findings regarding this method is pre­
sented in Table 1. Mild and moderate steatohepatitis were 
defined as conditions in which < 33% and 33%-66% of  
hepatocytes were affected, respectively; whereas, severe 
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steatohepatitis was characterized with > 66% involvement 
of  hepatocytes. Additionally, advanced fibrosis consisted 
of  bridging fibrosis (grade Ⅲ) and cirrhosis. In order to 
restrict the information bias, a single pathologist reported 
all histopathologic findings. The mean grade of  all patho­
logic findings were also calculated according to Brunt 
scoring values.
All laboratory and histopathologic features of  enrolled 
NASH patients were evaluated and compared between 
two gender (male vs female) and age (< 55 years as young­
er vs ≥ 55 years as older patients) groups.
Statistical analysis
The data were analyzed using SPSS v.15 software for 
Windows (Chicago, USA). Descriptive data were reported 
using parameters such as frequency, mean, mode and SD. 
Kolmogorov­Smirnov test was performed to evaluate 
normal distribution of  the quantitative variables. To test 
the differences between parametric and non­parametric 
variable means in the two study groups, independent T­test 
and Mann-Whitney U­test were used. 
To compare the differences between the frequency 
of  qualitative variables between study groups Chi square 
test was performed. Moreover, in order to evaluate the 
confounding effects of  age on the association between 
histopathologic findings and gender, univariate analysis 
was used. Receiver operating characteristics (ROC) curve 
analysis was also performed to assess the predictability of  
advances in histopathologic findings with patients’ age, 
and the area under curve (AUC) and the best cutoff  value 
were determined. The appropriate diagnostic values of  
each cutoff  point were reported, including sensitivity and 
specificity. 
A 5% probability of  a type Ⅰ error (two-tailed), and 
a power of  80% were considered in the analysis. All re­
ported P­values are two­tailed.
RESULTS
Baseline characteristics
A total of  77 NASH patients were enrolled in this study, 
consisting of  58 males (75.3%) and 19 (24.7%) females 
with a mean age of  41.99 ± 11.80 years (range, 18-70 years). 
Baseline characteristics including paraclinical data are 
listed in Table 2. As shown, the mean serum levels of  liver 
enzymes including ALT, AST and Alk-P were 117.73 ± 
237.52 U/L, 58.29 ± 27.77 U/L and 176.48 ± 96.95 U/L, 
respectively.
As mentioned before, all patients underwent liver bi­
opsy and the results are shown in Table 3. The most com­
mon grade of  hepatosteatosis was grade Ⅰ in 36 patients 
(46.8%) and liver cirrhosis was detected in 5 patients 
(6.7%). 
Characteristic and histopathologic features of NASH 
patients regarding different sex groups
Baseline and clinical characteristics of  NASH patients are 
listed in Table 2. As shown, the mean age of  female pa­
tients was significantly higher than male patients (48.72 ± 
13.99 years vs 39.74 ± 10.16 years, P = 0.004). In addition, 
the mean serum level of  AST was also significantly higher 
in females (75.11 ± 29.68 U/L vs 52.78 ± 25.00 U/L, P = 
0.002). Other baseline and clinical characteristics were not 
significantly different between the two gender groups.
Different histopathologic findings of  the patients 
are presented in Table 3. The most common grade of  
hepatosteatosis in males was grade Ⅰ in 51.7% (30/58); 
whereas, the commonest grade in females was grade Ⅱ 
with a prevalence of  36.8% (7/19). Moreover, the mean 
quantitative grade of  hepatosteatosis was significantly 
higher in females (2.00 ± 0.82 vs 1.59 ± 0.68, P = 0.031). 
Advanced fibrosis (consisting of  grade Ⅲ and cirrhosis) 
was reported in 8.8% (5/58) and 16.7% (3/19) of  males 
and females, respectively. The mean grade of  fibrosis was 
also higher in females (1.22 ± 1.35 vs 0.88 ± 1.05). How­
ever, these differences were not statistically significant (P 
= 0.563 and 0.263). As shown in Table 3, other histopath­
ologic findings were not statistically different between the 
two gender groups of  the NASH patients.
Characteristic and histopathologic features of NASH 
patients regarding different age groups
Based on the data in Table 2, the mean serum level of  
ALT in patients aged < 55 years and ≥ 55 years was 
123.21 ± 260.49 U/L and 100.44 ± 91.57 U/L, respec­
tively, which showed no significant difference (P = 0.772). 
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Table 1  Histopathologic grading (Brunt)[18] of different 




   Grade Ⅰ < 33% of hepatocytes affected
   Grade Ⅱ 33%-66% of hepatocytes affected
   Grade Ⅲ > 66% of hepatocytes affected
Fibrosis 
   No fibrosis No fibrosis
   Grade Ⅰ Zone 3 perisinusoidal pericellular fibrosis, focally or 
extensively present
   Grade Ⅱ Zone 3 perisinusoidal pericellular fibrosis, with focal 
or extensive periportal fibrosis
   Grade Ⅲ Zone 3 perisinusoidal pericellular fibrosis and portal 
fibrosis with extensive or focal bridging fibrosis
   Cirrhosis Cirrhosis
Hepatocyte ballooning
   No ballooning No ballooning
   Grade Ⅰ Sometimes, zone 3
   Grade Ⅱ Evident, zone 3
   Grade Ⅲ Symptomatic, more dominant in zone 3
Lobar inflamation
   No change No change
   Grade Ⅰ Diffuse neutrophils, monocytes at 1 or 2 points in a 
20 × microscopic field
   Grade Ⅱ PMN with ballooning hepatocytes, chronic 
inflammation at 2 to 4 points in a 20 × microscopic field
Portal inflamation
   No change No change
   Grade Ⅰ Mild, some portal areas
   Grade Ⅱ Mild to moderate, most portal areas
   Grade Ⅲ Moderate to severe, most portal areas
PMN: Polymorphonuclear leukocyte.
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Similarly, the mean serum level of  AST was not statisti­
cally different between the two age groups of  patients 
(57.28 ± 28.17 U/L vs 57.89 ± 20.52 U/L, P = 0.951). 
Other baseline and clinical characteristics were not sig­
nificantly different between the two age groups.
Table 3 shows the histopathologic findings of  NASH 
patients regarding different age groups. While 54% 
(34/65) of  younger patients had mild hepatosteatosis 
(Grade Ⅰ), only one patient (11.2%) in the older group 
had grade Ⅰ hepatosteatosis. On the other hand, the older 
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Table 2  Baseline and clinical characteristics of non-alcoholic steatohepatitis patients regarding different sex and age groups  (mean ± SD)
Variable Total (n  = 77) Sex groups P -value Age groups P -value
Male (n  = 58) Female (n  = 19) < 55 yr (n  = 65) ≥ 55 yr (n  = 12)
Age (yr)   41.99 ± 11.80   39.74 ± 10.16   48.72 ± 13.99  0.004a - - -
Gender, n (%)
   Female 19 (24.7) - - - 14 (21.5) 5 (41.6) 0.214
   Male 58 (75.3) 51 (78.5) 7 (58.4)
BMI (kg/m2) 28.62 ± 3.42 28.86 ± 3.25 27.81 ± 4.00 0.336 28.74 ± 3.55 26.87 ± 2.52 0.186
Fasting blood sugar (mg/dL) 107.37 ± 47.60 103.16 ± 47.39 121.14 ± 47.14 0.195 107.88 ± 52.06 114.12 ± 25.85 0.742
Total cholesterol (mg/dL) 197.29 ± 47.81 192.07 ± 45.52 212.68 ± 52.26 0.105 197.07 ± 46.98 200.67 ± 37.82 0.827
Triglyceride (mg/dL)   202.26 ± 118.13 201.72 ± 97.26   203.89 ± 169.65 0.947   206.40 ± 121.92   202.33 ± 100.36 0.876
LDL-cholesterol (mg/dL) 119.09 ± 39.20 119.87 ± 35.00 117.13 ± 49.64 0.822 118.27 ± 38.74 134.43 ± 40.13 0.313
HDL-cholesterol (mg/dL)   46.61 ± 24.53   44.97 ± 25.20   50.87 ± 22.97 0.301   47.86 ± 26.45   40.12 ± 13.68 0.891
PTT (s) 12.47 ± 1.50 12.39 ± 1.66 12.72 ± 0.86 0.846 12.45 ± 1.58 12.40 ± 1.52 0.842
Platelet count (/L) 358 505 ± 48 852 357 505 ± 52 403 361 125 ± 39 954 0.122 395 325 ± 55 385 237 385 ± 63 753 0.964
ALT (U/L)   117.73 ± 237.52   92.05 ± 60.72   196.11 ± 466.82 0.943   123.21 ± 260.49 100.44 ± 91.57 0.772
AST (U/L)   58.29 ± 27.77   52.78 ± 25.00   75.11 ± 29.68  0.002a   57.28 ± 28.17   57.89 ± 20.52 0.951
Alk-P (U/L) 176.48 ± 96.95 171.14 ± 92.19   192.21 ± 111.00 0.417 176.11 ± 94.50   183.44 ± 128.40 0.837
γ-GTP (U/L)   29.55 ± 28.40   28.69 ± 30.95   31.42 ± 24.47 0.852 28.74 ± 3.55 15.17 ± 3.76 0.333
aStatistically significant. BMI: Body mass index; LDL: Low density lipoprotein; HDL: High density lipoprotein; PTT: Partial thromboplastin time; ALT: 
Alanine aminotransferase; AST: Aspartate aminotransferase; Alk-P: Alkaline phosphatase; γ-GTP: γ-glutamyl transpeptidase.
Table 3  Histopathologic characteristics of non-alcoholic steatohepatitis patients regarding different sex and age groups (mean ± SD)  n (%)
Finding Total (n  = 77) Sex groups P -value Age groups P -value
Male (n  = 58) Female (n  = 19) < 55 yr (n  = 65) ≥ 55 yr (n  = 12)
Hepatosteatosis 
   Grade Ⅰ 36 (46.8) 30 (51.7)   6 (31.6)             34 (54) 1 (11.2)
   Grade Ⅱ 29 (37.7) 22 (37.9)   7 (36.8) 0.068 23 (36.5) 4 (44.4)  0.007a
   Grade Ⅲ 12 (15.6)   6 (10.3)   6 (31.6) 6 (9.5) 4 (44.4)
   Mean grade 1.69 ± 0.73 1.59 ± 0.68 2.00 ± 0.82  0.031a 1.56 ± 0.67 2.33 ± 0.71  0.002a
Fibrosis 
   No fibrosis 31 (41.3) 24 (42.1)   7 (38.9) 27 (44.3) 2 (22.2)
   Grade Ⅰ 29 (38.7) 24 (42.1)   5 (27.8) 22 (36.1) 4 (44.4)
   Grade Ⅱ 7 (9.3)            4 (7)   3 (16.7) 0.563 6 (9.8) 1 (11.1) 0.307
   Grade Ⅲ            3 (4) 2 (3.5) 1 (5.6) 3 (4.9) -
   Cirrhosis 5 (6.7) 3 (5.3)   2 (11.1) 3 (4.9) 2 (22.2)
   Mean grade 0.96 ± 1.13 0.88 ± 1.05 1.22 ± 1.35 0.263 0.91 ± 1.09 1.56 ± 1.51 0.115
Hepatocyte ballooning
   No ballooning 52 (72.2) 41 (74.5) 11 (64.7) 42 (71.2)              6 (75)
   Grade Ⅰ 12 (16.7)   8 (14.5)   4 (23.5) 0.224 11 (18.6) 1 (12.5) 0.935
   Grade Ⅱ 7 (9.7)   6 (10.9) 1 (5.9) 5 (8.5) 1 (12.5)
   Grade Ⅲ 1 (1.4) - 1 (5.9) 1 (1.7) -
   Mean grade 0.40 ± 0.72 0.36 ± 0.68 0.53 ± 0.87 0.448 0.41 ± 0.72 0.37 ± 0.74 0.864
Lobar inflammation
   No change 25 (36.8) 23 (42.6)   2 (14.3) 18 (31.6) 6 (100)
   Grade Ⅰ 37 (54.4)          27 (50) 10 (71.4) 0.138 34 (59.6) -  0.005a
   Grade Ⅱ 6 (8.8) 4 (7.4)   2 (14.3) 5 (8.8) -
   Mean grade 0.72 ± 0.62 0.65 ± 0.62 1.00 ± 0.55 0.052 0.77 ± 0.60 -  0.004a
Portal inflammation
   No change 41 (55.3) 33 (58.9)   8 (44.4) 35 (58.3) 3 (33.3)
   Grade Ⅰ 25 (33.8) 19 (33.9)   6 (33.3) 19 (31.7) 5 (55.6)  0.045a
   Grade Ⅱ 6 (8.1) 3 (5.4)   3 (16.7) 0.192 5 (8.3) -
   Grade Ⅲ 2 (2.8) 1 (1.8) 1 (5.6) 1 (1.7) 1 (11.1)
   Mean grade 0.59 ± 0.81 0.52 ± 0.76 0.83 ± 0.92 0.163 0.55 ± 0.79 0.89 ± 0.93 0.200
aStatistically significant. 
Daryani NE et al . Influence of age and gender in NASH
patients had suffered significantly more severe hepatos­
teatosis (Grade Ⅲ) (44.4% vs 9.5%, P = 0.007). More­
over, the mean quantitative grade of  hepatosteatosis was 
significantly higher among patients with an age of  ≥ 55 
years (2.33 ± 0.71 vs 1.56 ± 0.67, P = 0.002). Although the 
prevalence of  any grade of  fibrosis was also higher in old­
er patients, this difference was not statistically significant 
(77.8% vs 54.7%, P = 0.307). By contrast, lobar and portal 
inflammation were reported significantly more often in 
histopathologic findings of  younger NASH patients (P = 
0.005 and 0.045, Table 3). 
More detailed analysis was performed to evaluate the 
best cutoff  points of  patients’ age to predict advances in 
histopathologic findings. First, the results of  ROC curve 
analysis showed that the values of  patients’ age could 
significantly differentiate NASH patients with or without 
advanced fibrosis (AUC = 0.734, P = 0.032). Addition­
ally, the cutoff  value of  50 years had 62.5% sensitivity and 
78.1% specificity to predict advanced fibrosis; whereas, 
the cutoff  point of  45.5 years had a sensitivity of  75% 
and specificity of  69.7%.
Age and sex interactions
According to the above, female patients were significantly 
older than males (P = 0.004); therefore, multivariate analy­
sis was performed to evaluate the confounding role of  
age in the association between gender and histopathologic 
findings (especially the mean grade of  hepatosteatosis). 
The results emphasized the higher grade of  hepatosteato­
sis in female patients even when considering patients’ age 
as a fixed covariate between two genders (P = 0.010). 
After omitting the patients aged > 50 years, the mean age 
of  two gender groups were matched (36.87 ± 11.11 years 
in females vs 36.40 ± 7.25 years in males); and again the 
mean grade of  hepatosteatosis was higher in female NASH 
patients (1.87 ± 0.83 vs 1.49 ± 0.62).
Furthermore, when both age and sex were considered 
(by dividing the patients into four groups), the more se­
vere hepatosteatosis were reported in female patients aged 
≥ 55 years (Figure 1A) while the mildest histopathologic 
findings were found in younger males (Figure 1A and B). 
DISCUSSION
It has been suggested that some patients with NASH may 
manifest a benign course where others follow a more ag­
gressive course which results in cirrhosis and final liver 
failure. The basis for this unusual course in patients suffer­
ing from the identical situation proposes that the disease 
might have a benign and non­aggressive course in some 
patients whereas, in patients with more aggressiveness 
some factors may contribute and aggravate the consequent 
liver damage and fibrosis which can finally result in cir­
rhosis. For the last two decades, several studies have con­
sidered different issues as possible risk factors for NASH 
such as hyperlipidemia, hypertension and insulin resis­
tance. Unlike these studies, we did not focus on metabolic 
syndrome because these risk factors have been studied 
in many previous reports[19,20] but we have tried to dem­
onstrate some of  the factors which are believed to play a 
role in disease severity and pathological findings in Iranian 
patients suffering from NASH. However, it is noted that 
the prevalence of  the known risk factors of  metabolic dis­
orders were not significantly different between the two age 
and gender groups in our study (Table 2). 
This study has revealed some important points which 
need to be discussed further. First, the severity of  hepa­
tosteatosis and portal inflammation increases with age. 
Second, female patients being affected are older. Third, 
hepatosteatosis is more severe in female patients even af­
ter age-adjustment and finally, female patients have higher 
AST levels.
Early studies had considered female gender as a risk 
factor for NASH but this was not identified by recent 
studies[9,21]. Angulo et al[22] reported that there is a trend 
toward higher levels of  fibrosis in female patients with 
NASH but in another study on children suffering from 
NASH such a relationship was not reported[23]. Ratziu 
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Figure 1  Frequency of different grades of hepatosteatosis (A) and fibrosis (Brunt) (B) in non-alcoholic steatohepatitis patients regarding their gender and 
age groups.
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et al[24] studying the clinical and pathological aspects of  
NASH in Japanese patients concluded that older patients 
have more severe fibrosis compared to younger adults 
where the older group consisted of  significantly more fe­
males. According to these findings they considered female 
gender as a possible risk factor for NASH severity but ac­
cording to multivariate analysis on both age groups, gen­
der had no role in the severity of  the liver involvement. 
Likewise, level of  fibrosis was higher in female patients 
in this study, but there was not a significant difference 
among different genders. The only significant difference 
considering age and pathological findings was the level of  
hepatosteatosis. In contrast to the study of  Yatsuji et al[25], 
our findings highlighted the significantly higher grade of  
hepatosteatosis in female patients despite the elimination 
of  the confounding role of  patients’ age in this associa­
tion.
Patients aged ≥ 55 years of  age had significantly high­
er levels of  hepatosteatosis compared to younger patients. 
Although the level of  fibrosis was not significantly differ­
ent, older patients had considerably more severe portal 
inflammation and less lobar inflammation. In addition, 
results of  ROC curve analysis showed that the cutoff  val­
ues of  50 or 45.5 years for patients’ age could significantly 
differentiate NASH patients with or without advanced 
fibrosis.
Previous studies suggested a number of  factors as­
sociated with more severe and progressive liver fibrosis. 
In one study focusing on obese patients, age ≥ 50 years 
[odds ratio (OR) 14.1], a body mass index ≥ 28 kg/m2 
(OR 5.7), triglycerides ≥ 1.7 mmol/L (OR 5), and an 
ALT concentration ≥ 2 × normal (OR 4.6) were associ­
ated with more severe fibrosis[24]. In another study on 733 
patients, the authors presented a model consisting of  age, 
body mass index, platelet count, albumin, and AST/ALT 
ratio which had a good predictive value for advanced fi­
brosis[26]. 
As mentioned before, in a similar study on Japanese 
patients, the older patients had much more advanced 
fibrosis and worse deterioration of  liver function com­
pared to the younger group[25]. Age related mitochondrial 
dysfunction has been suggested recently as a contributing 
factor in developing insulin resistance[27]. Pathophysiologi­
cal considerations, laboratory investigations and clinical 
association studies have supported the central role of  
mitochondrial dysfunction in developing insulin resistance 
and subsequent liver disease[20,28-30].
More recently, a systematic review was performed for 
assessment of  factors associated with fibrosis progression 
in NASH patients by Argo et al[31]. They involved patients 
with one initial liver biopsy and one or more biopsies 
during the course of  disease and revealed that age and 
initial level of  fibrosis are the only predictors of  fibrosis 
progression. Compared to their findings our results also 
showed that advanced age contributed to higher grades of  
hepatosteatosis and portal inflammation but such a rela­
tionship was not found with gender. However, the most 
severe grade of  hepatosteatosis was found in older female 
patients.
Unfortunately previous studies comparing different 
components of  Brunt classification of  liver pathology ac­
cording to independent risk factors are scarce and more 
precise studies with a greater study population are needed 
to correctly evaluate the relationship between these factors 
and liver pathology. 
In conclusion, our data points toward the possible 
influence of  age in the severity of  steatohepatitis, portal 
and lobar inflammation in patients suffering from NASH 
and also indicates that gender independently contributed 
to the level of  steatohepatitis. Moreover, according to 
the lower cutoff  values of  50 or 45.5 years of  age for 
advanced fibrosis in Iranian patients, it might be possible 
to consider progression toward cirrhosis earlier (before 
55 years) in an Iranian population. 
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might contribute to the level of steatohepatitis. Severity of steatohepatitis, portal 
and lobar inflammation is higher in older patients suffering from NASH.
Applications
Physicians should be more cautious while treating older and female patients as 
these groups might have more severe pathologic findings in their liver biopsies.
Peer review
This manuscript is interesting. The number of patients included in the study is 
small and may underestimate the frequency of NASH.
REFERENCES
1 Harrison SA, Torgerson S, Hayashi PH. The natural history 
of nonalcoholic fatty liver disease: a clinical histopathologi-
cal study. Am J Gastroenterol 2003; 98: 2042-2047
2 Rivera CA. Risk factors and mechanisms of non-alcoholic 
steatohepatitis. Pathophysiology 2008; 15: 109-114
3 Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri 
BA. Nonalcoholic steatohepatitis: an expanded clinical en-
tity. Gastroenterology 1994; 107: 1103-1109
4 Diehl AM, Goodman Z, Ishak KG. Alcohollike liver dis-
ease in nonalcoholics. A clinical and histologic comparison 
with alcohol-induced liver injury. Gastroenterology 1988; 95: 
1056-1062
5 Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, 
Benson JT, Enders FB, Angulo P. The natural history of non-
alcoholic fatty liver disease in children: a follow-up study for 
up to 20 years. Gut 2009; 58: 1538-1544
6 Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. 
Hum Pathol 1989; 20: 594-598
7 Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, 
Powell LW. The natural history of nonalcoholic steatohepati-
4174 September 7, 2010|Volume 16|Issue 33|WJG|www.wjgnet.com
 COMMENTS
Daryani NE et al . Influence of age and gender in NASH
4175 September 7, 2010|Volume 16|Issue 33|WJG|www.wjgnet.com
tis: a follow-up study of forty-two patients for up to 21 years. 
Hepatology 1990; 11: 74-80
8 Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, 
Feldstein A, Angulo P. The natural history of nonalcoholic 
fatty liver disease: a population-based cohort study. Gastro-
enterology 2005; 129: 113-121
9 Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic 
steatohepatitis: Mayo Clinic experiences with a hitherto un-
named disease. Mayo Clin Proc 1980; 55: 434-438
10 Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, 
Bugianesi E, McCullough AJ, Forlani G, Melchionda N. As-
sociation of nonalcoholic fatty liver disease with insulin re-
sistance. Am J Med 1999; 107: 450-455
11 Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, 
Manini R, Natale S, Vanni E, Villanova N, Melchionda N, 
Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the 
metabolic syndrome. Hepatology 2003; 37: 917-923
12 Pinto HC, Baptista A, Camilo ME, Valente A, Saragoça A, de 
Moura MC. Nonalcoholic steatohepatitis. Clinicopathologi-
cal comparison with alcoholic hepatitis in ambulatory and 
hospitalized patients. Dig Dis Sci 1996; 41: 172-179
13 Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) 
and obesity: an autopsy study with analysis of risk factors. 
Hepatology 1990; 12: 1106-1110
14 Charlton M. Cirrhosis and liver failure in nonalcoholic fatty 
liver disease: Molehill or mountain? Hepatology 2008; 47: 
1431-1433
15 Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda 
Y, Takeda R. Clinicopathologic study of alcohol-like liver 
disease in non-alcoholics; non-alcoholic steatohepatitis and 
fibrosis. Gastroenterol Jpn 1992; 27: 521-528
16 Bechtold M, Palmer J, Valtos J, Iasiello C, Sowers J. Meta-
bolic syndrome in the elderly. Curr Diab Rep 2006; 6: 64-71
17 Kotani K, Tokunaga K, Fujioka S, Kobatake T, Keno Y, Yo-
shida S, Shimomura I, Tarui S, Matsuzawa Y. Sexual dimor-
phism of age-related changes in whole-body fat distribution 
in the obese. Int J Obes Relat Metab Disord 1994; 18: 207-212
18 Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-
Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal 
for grading and staging the histological lesions. Am J Gastro-
enterol 1999; 94: 2467-2474
19 Marchesini G, Forlani G. NASH: from liver diseases to met-
abolic disorders and back to clinical hepatology. Hepatology 
2002; 35: 497-499
20 Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depe-
tris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. 
Nonalcoholic steatohepatitis, insulin resistance, and meta-
bolic syndrome: further evidence for an etiologic association. 
Hepatology 2002; 35: 367-372
21 Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from 
steatosis to cirrhosis. Hepatology 2006; 43: S99-S112
22 Angulo P, Keach JC, Batts KP, Lindor KD. Independent pre-
dictors of liver fibrosis in patients with nonalcoholic steato-
hepatitis. Hepatology 1999; 30: 1356-1362
23 Ko JS, Yoon JM, Yang HR, Myung JK, Kim HR, Kang GH, 
Cheon JE, Seo JK. Clinical and histological features of non-
alcoholic fatty liver disease in children. Dig Dis Sci 2009; 54: 
2225-2230
24 Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, The-
odorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver 
fibrosis in overweight patients. Gastroenterology 2000; 118: 
1117-1123
25 Yatsuji S, Hashimoto E, Tobari M, Tokushige K, Shiratori K. 
Influence of age and gender in Japanese patients with non-
alcoholic steatohepatitis. Hepatol Res 2007; 37: 1034-1043
26 Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Far-
rell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, 
Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, 
Day CP. The NAFLD fibrosis score: a noninvasive system 
that identifies liver fibrosis in patients with NAFLD. Hepatol-
ogy 2007; 45: 846-854
27 Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Roth-
man DL, DiPietro L, Cline GW, Shulman GI. Mitochondrial 
dysfunction in the elderly: possible role in insulin resistance. 
Science 2003; 300: 1140-1142
28 Bugianesi E, McCullough AJ, Marchesini G. Insulin resis-
tance: a metabolic pathway to chronic liver disease. Hepatol-
ogy 2005; 42: 987-1000
29 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steato-
hepatitis: summary of an AASLD Single Topic Conference. 
Hepatology 2003; 37: 1202-1219
30 Sanyal AJ. AGA technical review on nonalcoholic fatty liver 
disease. Gastroenterology 2002; 123: 1705-1725
31 Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Sys-
tematic review of risk factors for fibrosis progression in non-
alcoholic steatohepatitis. J Hepatol 2009; 51: 371-379
S- Editor  Wang JL    L- Editor  O'Neill M    E- Editor  Lin YP
Daryani NE et al . Influence of age and gender in NASH
